The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development (Cooperative Agreement, Clinical Trial Optional)

The Accelerating Medicines Partnership in Common Metabolic Diseases Knowledge Portal (AMP CMD KP) funding opportunity, administered by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), seeks to continue a pivotal initiative aimed at understanding the genetic architecture of common metabolic diseases (CMDs). This Notice of Funding Opportunity (NOFO), issued as RFA-DK-26-313, is a reissue of RFA-DK-19-505 and is structured as a non-competitive, single-source award intended solely for the current recipient, the Broad Institute, Inc. The AMP CMD KP serves as a major collaborative resource developed under the larger Accelerating Medicines Partnership (AMP), which involves NIH, industry, and nonprofit partners to foster pre-competitive biomedical research. The overarching objective is to facilitate the identification and validation of biological targets relevant to CMDs—such as obesity, type 2 diabetes, cardiovascular disease, liver diseases, and chronic kidney disease—by aggregating and analyzing comprehensive human genomic and -omics data. This initiative addresses the complex interplay of genetic and environmental factors in CMDs, highlighting the limitations of traditional research approaches in isolating causal variants and associated transcripts, especially in non-coding regions of the genome. AMP CMD KP has become the flagship data resource that integrates diverse publicly available datasets including genomic, epigenomic, phenotypic, and other functional data. The next funding cycle seeks to maintain and expand this repository by continuing to curate high-value datasets, developing additional analytic and visualization tools, and enhancing accessibility for a diverse research community. This will be critical to enabling deeper understanding of the heterogeneity of CMD presentations and complications, identifying molecular networks driving disease, and ultimately uncovering actionable biomarkers and therapeutic targets. This funding mechanism supports a cooperative agreement (U01 activity code) over a five-year project period, with a budget ceiling of $2 million in direct costs annually and a total program budget of $15 million. The AMP CMD KP itself will not generate new data; rather, it will provide a secure, curated infrastructure and user-friendly portal for data analysis and dissemination. Applicants are expected to maintain a robust data management and sharing plan, ensuring that data are deposited in a timely manner and made accessible without intellectual property restrictions. The publicly accessible knowledge portal will cater to a range of users, from clinicians to researchers, and will interoperate with related databases and initiatives to broaden its utility. Eligible applicants are strictly limited to the Broad Institute, Inc., the current awardee under the previous NOFO. This single-source restriction is based on the unique expertise and existing infrastructure developed under the prior award. International organizations are not eligible, although U.S. organizations may include foreign components if compliant with NIH policies. Foreign subawards, however, are explicitly prohibited under this NOFO. The application process involves full adherence to NIH’s standard application and submission procedures, including use of platforms such as ASSIST or Grants.gov, and requires compliance with all applicable registration and submission guidelines outlined in the NIH Application Guide. The application window opens on February 6, 2026, with a submission deadline of March 6, 2026, at 5:00 PM local time. Peer review will take place in July 2026, with advisory council review expected in October 2026. The earliest start date for the award is December 2026. Although this NOFO is non-competitive in scope, it is still subject to NIH's rigorous peer review standards, and funding will be contingent upon a meritorious application. The evaluation will consider significance, innovation, scientific rigor, feasibility, and investigator qualifications, along with institutional support and resource availability. For inquiries, applicants may contact the NIDDK Division of Diabetes, Endocrinology and Metabolic Diseases at [email protected] for scientific and research-related questions. Financial or administrative questions may be directed to the NIDDK Grants Management Branch at [email protected]. The official NOFO posting includes all instructions, review criteria, and award administration details and should be carefully consulted to ensure complete and compliant submissions.

Emphasize rigor, feasibility, and plans for broad data sharing; peer review will be merit-based despite single-source